Abstract: We developed a porous chitosan/ hydroxyapatite (HAp) composite, in which the HAp nanocrystals align along the chitosan molecules, and examined the biocompatibility, osteoinductive activity, and the ability to act as a carrier of recombinant human bone morphogenetic protein-2 (rhBMP-2) of this novel biomaterial. The composite was subcutaneously implanted into the backs of 11-week-old SD rats, with or without rhBMP-2 (5 µg). At 2 and 8 weeks after the implantation, the composite was explanted for morphohistological evaluation. In the presence of rhBMP-2, ectopic bone formation was found at 2 weeks and maturation of the newly formed bone around the composite at 8 weeks. Chitosan/HAp composite alone caused little inflammation, and new blood vessel growth and multinucleated giant cells were found around the composite, accompanied with roughening of the surface due to degradation at 2 weeks; however, neither cartilage nor bone formation was found around the composite. With rhBMP-2, the bioabsorption of the composite was accelerated as the rhBMP-2-induced bone matured. Histomorphometrical analysis showed that the mean value of the composite areas with rhBMP-2 was significantly smaller than that without rhBMT-2 at 2 and 8 weeks after the implantation. These results suggested that the novel chitosan/ HAp composite was an effective bioabsorbable material as a carrier of rhBMP-2.
Introduction
Hydroxyapatite (HAp: Ca 10 (PO 4 ) 6 (OH) 2 ) has been used as a biocompatible and osteoconductive substitute in the fields of orthopedic, craniofacial, and dental surgeries 1, 2) . However, due to its hardness and brittleness, HAp ceramics are difficult to shape into the specific forms required for bone substitution. HAp powder, used for the treatment of bone defects, has also the problem that it easily migrates from the implanted sites. Novel composites of HAp and organic polymers are arousing great interest because of their potential to compensate for such mechanically weak properties of HAp 3, 4) .
Among the organ polymers, chitosan is an N-deacetylation product of chitin. It consists of glucosamine and Nacetylglucosamine units linked with 1-4 glycosidic bonds. In commercially available chitosan products, the acetyl content rates vary from 5 to 30 % due to imperfect N-deacetylation of chitin.
The most important feature of chitosan is its biodegradability 5) , while it has a good solubility in various organic acid solutions and sufficient resistance to alkali environments. Furthermore, chitosan is flexible and has high resistance upon heating due to the intramolecular hydrogen bonds formed between hydroxyl and amino groups [6] [7] [8] . The composite biomaterial of HAp and chitosan is therefore thought to exert increased osteoconductivity and biodegrading activity, with sufficient mechanical strength for orthopedic or dental use. To this day, various methods to develop HAp/chitosan composites have been reported, such as mixing HAp powder in a chitosan solution 9) , or coating a chitosan sheet with homogeneous chitosan/HAp composite with various porosities, in which the HAp nanocrystals align along the chitosan molecules 11) . The spongy composite was found to be mechanically flexible and easily formed into any desired shape.
One of the important points in clinical use of biomaterials is that they must be not only biocompatible but also stable immediately after they are implanted. To facilitate bone formation and shorten the time for bone union, recombinant human bone morphogenetic proteins (rhBMPs) are available, which are known to induce ectopic bone formation in skeletal and nonskeletal sites [12] [13] [14] . To introduce rhBMPs, biocompatible carriers are indispensable, and many carriers have already been reported 15, 16) . For example, β-tricalcium phosphate (β -TCP) 17) , biphasic calcium phosphate (BCP) 18) , and insoluble bone matrix (IBM) 19) have good osteoconductive activities, but their mechanical properties are far inferior to cortical bone tissue; ceramics 1, 2) shows a superior osteoconductive activity and mechanical property, but it is not bioabsorbable and thus clinical problems may occur after its implantation. For these reasons, to develop a new biocompatible carrier to introduce rhBMPs is required.
The present study was designed to evaluate the osteoinductive efficacy of a newly developed porous chitosan/ HAp composite as a bioabsorbable carrier of rhBMP-2 in the subcutaneous tissue of rats.
Materials and Methods

Synthesis of the porous chitosan/ HAp composite
Chitosan powder was obtained from Hokkaido Soda Co. water (approx. 50°C) for about 12 hours each. Figure 1 shows a macroappearance and scanning electron microscopic (SEM) photographs of the composite. The spongy composite was found to be mechanically flexible and could be easily formed into any desired shape; it soon recovered the original form by itself, if deformed with forces. The interconnected porous structure was observed in SEM images (porosity: 60-90%, pore diameter: 100-300µm) 11) . For all the composites, comparatively homogeneous Co.,Ltd., Osaka, Japan). After their backs were shaved and disinfected with 70% ethyl alcohol, shallow incisions were made in the skin of their backs, and pockets were created. The composite with or without rhBMP-2 (5µg) was subcutaneously inserted in the left pocket (below the subcutaneous muscle layers) and the skin was closed with cotton sutures. Three rats were sacrificed respectively at 2 and 8 weeks after the implantation.
Histological observations
The implanted pieces of the composite were removed and fixed in 10% neutral buffered formalin, dehydrated and cleared with graded alcohols and xylol, and embedded in paraffin wax.
Sectioned at 5 µm thickness with a microtome, the paraffin waxembedded specimens were stained with hematoxylin and eosin
(H & E). Histological observation and recording were carried out
with an optical microscope (Olympus BX-51, Tokyo, Japan). For morphometric analysis, tissues of the implant areas at 2 and 8 weeks were respectively divided into three parts: bone tissue that included newly formed bone and marrow, the composite residues that had little or no cellular invasion, and connective tissue that contained a certain number of mesenchymal cells. Those three parts were measured respectively by using Weibel's method 21, 22) at three separate points 100 µm apart, the midpoint being at the center of the implant. The average values of the three points respectively at 2 and 8 weeks after the implantation were compared. The statistical significance of the data was evaluated by Mann-Whitney U-test.
Results
Histological findings
The In contrast, on the surface of the composite with rhBMP-2, ectopic bone formation occurred at 2 weeks (Figure 2d, e) .
Absorption of the composite proceeded in the surface and depth.
Blood vessel and connective tissue invaded in the pores. At 8 weeks, maturation of the newly formed bone prevailed over the composite through a trabeculae structure development (Figure 2f ).
The bioabsorption of the composite was accelerated as rhBMP-2-induced bone matured.
Histomorphometrical analysis
The morphometric results are shown in Table I 
Discussion
Many reports show that HAp ceramics may be used as substitutes for autogenous bone grafts in bone defects [23] [24] [25] [26] . The disadvantages of HAp ceramics are, however, (a) fragility under We developed a novel chitosan/HAp composite with various porosities, using the co-precipitation and porogen-leaching method 11) . The spongy composite was found to be mechanically flexible and could be easily formed into any desired shape; it does not easily break either with tensile or compressive force, and if deformed with force, it soon recovers the original form by itself.
The mechanical properties of the composite have been improved by heat treatment with saturating steam, which is ascribed to the formation of hydrogen bonds among chitosan molecules 11, 20) . The elasticity and flexibility will contribute to easy handling in surgical operations. SEM observations confirmed the interconnected porous structure (porosity: 60-90%, pore diameter: 100-300 µm).
A previous research suggested that human osteoblasts can penetrate pores >20 µm in size 27) , and the porosity needs to be >30% to achieve interconnection 28) . The porosity of the composite scaffolds we developed was sufficient for good interconnection and supply of nutrition. Also, the pore size of the scaffolds could support the growth of cells. To evaluate the efficacy of the newly developed composite as a carrier of rhBMP-2, we subcutaneously implanted it into the backs of SD rats, with or without rhBMP-2 (5 µg). The composite with rhBMP-2 implant resulted in ectopic bone formation and the accelerated bioabsorption of the composite harmonized with bone remodeling. These results suggested that the novel chitosan/ HAp composite was an effective bioabsorbable material for the delivery of rhBMP-2 and bone engineering.
